Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meth bill

This article was originally published in The Tan Sheet

Executive Summary

"Methamphetamine Blister Pack Loophole Elimination Act of 2004" (HR 3789), introduced in House Feb. 10 by Collin Peterson (D-Minn.), mirrors bill introduced by Sen. Dianne Feinstein (D- Calif.). Bill would eliminate exemption for blister-pack pseudoephedrine products from 9 g sales limit on bottled products (1"The Tan Sheet" Oct. 27, 2003, In Brief)...

You may also be interested in...



Meth blister pack bill

Blister-packed pseudoephedrine products would be subject to 9 gram retail sales limit applied to bottled products under "Methamphetamine Blister Pack Loophole Elimination Act of 2003" (S 1784) introduced Oct. 22 by Sen. Dianne Feinstein. Bill cites 2002 DEA study recommending limit, noting presence of blister packs at meth labs. Feinstein and others have introduced similar measures in the past. CHPA continues to object to uniform 9 g threshold, saying limit will not prevent diversion of products to labs. Bill was referred to Senate Judiciary Committee...

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel